Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2019 08:30 ET | Source: Optinose, Inc.

Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial

YARDLEY, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
November 26, 2019 16:01 ET | Source: Optinose, Inc.

Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference

YARDLEY, Pa., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
November 21, 2019 09:00 ET | Source: Optinose, Inc.

Optinose Announces Pricing of Public Offering of Common Stock

YARDLEY, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
November 20, 2019 16:00 ET | Source: Optinose, Inc.

Optinose Announces Proposed Public Offering of Common Stock

YARDLEY, Pa., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
November 12, 2019 16:01 ET | Source: Optinose, Inc.

Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

XHANCE net revenue grew 30% to $8.7 million from second to third quarter 2019 XHANCE prescriptions increased 27% from second to third quarter 2019 Company expects XHANCE net revenues for...
November 01, 2019 08:00 ET | Source: Optinose, Inc.

Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019

YARDLEY, Pa., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
October 04, 2019 08:00 ET | Source: Optinose, Inc.

Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

YARDLEY, Pa., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported...
September 27, 2019 08:00 ET | Source: Optinose, Inc.

Optinose to Present at the 2019 Cantor Global Healthcare Conference

YARDLEY, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
September 26, 2019 07:00 ET | Source: Optinose, Inc.

OptiNose Announces License Agreement Related to ONZETRA XSAIL

YARDLEY, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- OptiNose, Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists,...
September 17, 2019 16:01 ET | Source: Optinose, Inc.

Optinose Announces Departure of Chief Commercial Officer

YARDLEY, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...